One subtype of dermatomyositis, with anti-melanoma differentiation-associated gene 5 autoantibodies (anti-MDA5+), is associated with a higher risk of developing ILD and rapidly progressive ILD (RP-ILD) with a high mortality rate [2, 3]. This evidence concerns the gene IFIH1 and dermatomyositis.